Camille Jackson, MD
Gynecologic Oncology · Oklahoma City, OKNPI 1700046943
Payments from drug & device makers
Across 248 payments — averaging $3572.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Clovis Oncology, Inc.$321K
- Genentech, Inc.$267K
- Tesaro, Inc.$174K
- GSK$56K
- EMD Serono, Inc.$20K
- Intuitive Surgical$15K
- plus $34K from 36 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Clovis Oncology, Inc. | 45 | $320,841 |
| Genentech, Inc. | 3 | $266,933 |
| Tesaro, Inc. | 8 | $174,268 |
| GSK | 39 | $56,358 |
| EMD Serono, Inc. | 8 | $19,551 |
| Intuitive Surgical | 13 | $14,583 |
| Seagen Inc. | 4 | $14,548 |
| Pharmaand GmbH | 4 | $8,683 |
| Pfizer | 6 | $4,224 |
| AstraZeneca(2 entities) | 21 | $2,320 |
| Eisai Inc. | 13 | $1,628 |
| Medtronic | 6 | $357 |
| Merck | 11 | $270 |
| Myriad Genetic Laboratories, Inc. | 10 | $232 |
| Genmab U.S., Inc. | 6 | $134 |
| Novartis | 7 | $125 |
| AbbVie | 7 | $121 |
| Caris MPI, Inc. | 1 | $94 |
| Conmed Corporation | 1 | $83 |
| Mirati Therapeutics, Inc. | 4 | $82 |
| Johnson & Johnson | 3 | $61 |
| Amgen | 3 | $60 |
| Incyte Corporation | 3 | $53 |
| Lilly USA, LLC | 2 | $43 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Integra Lifesciences Corporation | 1 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Tempus AI, Inc | 1 | $29 |
| Kerecis Limited | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Immunogen, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| Dendreon Pharmaceuticals LLC | 1 | $21 |
| Bayer | 1 | $20 |
| Sobi, Inc | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Emmaus Medical, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Sanofi | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $10 |
How this compares
$886,061 in reported general payments places this provider in the 75th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Oklahoma City
- Debra RichardsonOklahoma City$8M
- Robert MannelOklahoma City$5.8M
- Lauren DockeryOklahoma City$3M
- Christina WashingtonOklahoma City$1.6M
- Tara CastellanoOklahoma City$68K
- Joan WalkerOklahoma City$11K
- Elizabeth EvansOklahoma City$3K
- Ana ValenteOklahoma City$2K
- Nicole MinaltOklahoma City$2K
- Jacqueline BohnOklahoma City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.